Muted end to FY20, promising FY21 pipeline
22/02/21 -"Smith & Nephew reported an in line Q4/FY20 top line (-7.1%/-12.1%). The Q4 decline was attributable to other reconstruction (-45.6%), knees (-16.2%) and ENT (-33.1%), while Hips surprised with a ..."
Pages
59
Language
English
Published on
22/02/21
You may also be interested by these reports :
23/02/26
Considering the lower medium-to-long-term expectations, the premium for peer-based metrics has been reduced to 25% (vs. 50% previously). However, ...
20/02/26
Since we began coverage on Elekta (BUY; Sweden) in January 2020, medical equipment and software provider for cancer treatment using radiation ...
18/02/26
Emeis delivered a robust operational recovery in 2025, characterised by EBITDAR growth that exceeded management guidance and a further strengthened ...
16/02/26
The target price benefits from higher earnings expectations, along with a 20% premium added to the peer-based valuation. This reflects the firm’s ...